In fact, the only available drug therapies for AD approved by the Food and Drug Administration (FDA) are targeting symptoms, such as cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and memantine, which is a N-methyl-D-aspartate (NMDA) receptor antagonist, and novel treatments have mostly failed in clinical studies, except for the expensive monoclonal antibody aducanumab (3) whose marketing authorization was however recently rejected by EMA (EMA/112932/2022 Rev.1); additionally, treatment of late stage AD with these drugs shows moderate results (4, 5). This evidence concerns the gene BCHE and Alzheimer disease.